Quarterly report pursuant to Section 13 or 15(d)

Revenue - Additional Information (Details)

v3.22.2.2
Revenue - Additional Information (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
Deferred revenue $ 2,091 $ 2,695
Contract with customer, liability, non-cancellable backlog 2,527  
Revenue recognized 1,618  
Deferred royalties 0 280
Accounts receivable, net of allowances 3,398 4,662
Accounts Receivable, Net And Other Assets    
Disaggregation of Revenue [Line Items]    
Accounts receivable, net of allowances 3,536 $ 4,824
Royalty    
Disaggregation of Revenue [Line Items]    
Revenue recognized 280  
Proceeds from upfront payment 300  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01    
Disaggregation of Revenue [Line Items]    
Remaining performance obligation, amount $ 375  
Remaining performance obligation, period 3 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01    
Disaggregation of Revenue [Line Items]    
Remaining performance obligation, amount $ 897  
Remaining performance obligation, period 1 year  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01    
Disaggregation of Revenue [Line Items]    
Remaining performance obligation, amount $ 819  
Remaining performance obligation, period  
Minimum    
Disaggregation of Revenue [Line Items]    
Accounts receivable payment terms 30 days  
Minimum | EksoHealth    
Disaggregation of Revenue [Line Items]    
Accounts receivable payment terms 12 months  
Maximum    
Disaggregation of Revenue [Line Items]    
Accounts receivable payment terms 90 days  
Maximum | EksoHealth    
Disaggregation of Revenue [Line Items]    
Accounts receivable payment terms 48 months